The metabolism of prostaglandin F2Α (PGF2Α) was investigated in the fetal cotyledons of human term placentas by an in vitro perfusion technique. When 80 nmol of 14C-PGF2Α was infused in 2 min into the chorionic artery, 56 ± 7% (mean ± SEM, n = 7) of the infused radioactivity appeared in the nonrecirculating venous effluent in 6 min. Most of this radioactivity was as unmetabolized PGF2Α· Only 12 ± 2% of the radioactivity in this venous effluent was as metabolites, the major metabolite being 13,14-dihydro-15-keto-PGF2Α. During the following 2 min, 2 ± 1 % of the infused radioactivity appeared in the venous effluent. The fluid trickling through the decidual plate contained 5 ± 1 % of the infused radioactivity. After the perfusion 10–15% of the infused radioactivity was retained in the tissue, being mainly as 13,14-dihydro-15-keto-PGF2Α· The oxygen consumption of the tissue was 0.4 ± 0.1 ml/100g/min, which is adequate for vital placenta tissue. The study suggests that the metabolism of PGF2Α is negligible in the fetal circulation of the human term placenta.

Keywords:
Prostaglandin F2α, Metabolism, Placenta, In vitro perfusion
This content is only available via PDF.
© 1984 S. Karger AG, Basel
1984
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.